3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Thyroid Nodule
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Skin Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
Biopsy, Needle
×
Clear all
NCT00715793
2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2
Completed
39 enrolled
12 charts